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ABSTRACT
Luminal breast tumors have been classified into A and B subgroups, with the luminal 
A being associated with a more favorable clinical outcome. Unfortunately, luminal A 
tumors do not have a universally good prognosis. We used transcriptomic analyses 
using public datasets to evaluate the differential expression between normal breast 
tissue and breast cancer, focusing on upregulated genes included in cell cycle function. 
Association of selected genes with relapse free survival (RFS) and overall survival (OS) 
was performed using the KM Plotter Online Tool (http://www.kmplot.com). Seventy-
seven genes were differentially expressed between normal and malignant breast tissue. 
Only five genes were associated with poor RFS and OS. The mitosis-related genes GTSE1, 
CDCA3, FAM83D and SMC4 were associated with poor outcome specifically in Luminal A 
tumors. The combination of FAM83D and CDCA3 for RFS and GTSE1 alone for OS showed 
the better prediction for clinical outcome. CDCA3 was amplified in 3.4% of the tumors, 
and FAM83D and SMC4 in 2.3% and 2.2%, respectively. In conclusion, we describe a 
set of genes that predict detrimental outcome in Luminal A tumors. These genes may 
have utility for stratification in trials of antimitotic agents or cytotoxic chemotherapy, 
or as candidates for direct target inhibition.
INTRODUCTION
Breast cancer has been classified in different 
subtypes by gene expression analyses, and each of these 
subtypes is associated with different clinical outcomes 
[1, 2]. The luminal subtype includes those tumors that 
express the estrogen receptor, and therefore can be 
targeted with hormonal therapy [1, 3]. This subgroup has 
been classified as luminal A and B, and similarly these two 
subtypes are associated with different clinical outcomes [1, 
4]. Luminal B tumors are linked with a more aggressive 
phenotype while luminal A shows a more benign behavior 
[4]. Luminal B tumors are characterized by an increased 
in proliferation, which is evidenced by elevated levels of 
Ki67 [5]. In addition, Luminal B tumors respond better to 
cytotoxic chemotherapy than the luminal A subtype.
It is known that the classification of breast cancer 
can stratify risk and prognosis; however not all tumors 
within a subgroup have similar clinical behavior. For 
instance, a subset of luminal A cancers are associated 
with poor outcome. Therefore the identification of these 
tumors could help to optimize therapy and to explore 
novel therapeutic strategies.
One of the main differences between the two 
luminal subgroups is the capacity of tumors to proliferate. 
However, measures of proliferation such as Ki67 are 
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imperfect and some tumors that depend of mitosis are 
not identified. Therefore, the recognition of luminal A 
tumors that are mitotically more active and associated with 
worse outcome could help clinicians to customize their 
therapeutic decisions.
We hypothesize that by evaluating dysregulated 
genes involved in cell cycle and that are overexpressed in 
other breast cancer subtypes, we can identify a set of genes 
that would permit us to select those luminal A tumors 
associated with worse outcome. The identification of this 
subgroup would have important clinical implications as it 
could help determine which patients will respond poorly to 
endocrine therapy, opening the possibility to explore other 
therapeutic options in this group.
RESULTS
Transcriptomic analysis identify upregulated 
genes linked with cell cycle
By comparing gene expression data from normal 
breast tissue and breast cancers, using a minimum fold 
change of 4, we identified 136 and 90 dysregulated genes 
included in the cell cycle function, in basal and non-basal 
breast cancers, respectively. Functional genomics using 
DAVID bioinformatic resources 6.7 identified several 
functions among the gene candidates (Figure 1A). A total 
number of 77 genes associated with cell cycle were shared 
among both basal and non-basal cancers (Figure 1A).
Mitotic-related genes GTSE, CDCA3, FAM83D 
and SMC4 are associated with poor outcome
Using the online tool KM plotter (http://www.
kmplot.com) [6] we selected genes that were associated 
with detrimental outcome specifically in luminal A tumors. 
The definition of breast cancer subtypes is described in 
material and methods. Among the 77 genes identified 
only 5 were associated with poor relapse free survival 
(RFS) and overall survival (OS) in the luminal A subtype 
(Figure 1B). One of the identified genes was MKi67, the 
gene that codes for Ki67. Therefore, we did not consider 
it for further outcome analyses as it is the gene used in 
the clinical setting to discriminate luminal A from luminal 
B subgroups. Of note, the predictive capacity for this 
gene was lower than the others selected, mainly for OS 
Figure 1: Identification of genes associated with detrimental outcome in Luminal A tumors. A. Transcriptomic expression 
and pathway analyses among normal breast and basal-like and non-basal-like breast cancers, with the identification of dysregulated genes 
with more than ≥4 fold change included in the cell cycle gene ontology categories. B. Outcome screening for detrimental relapse free 
survival and overall survival. Confirmation of expression values between normal breast and breast cancer using data contained at Oncomine.
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(HR: 1.4, CI: 1.17-1.67; log-rank p=0.00023 and HR: 
1.47, CI: 1.01-2.16; log-rank p=0.046, for RFS and OS, 
respectively).
The four selected genes were GTSE1, CDCA3, 
FAM83D and SMC4. Each gene was associated with 
detrimental RFS and OS in luminal A tumors as shown 
in Figure 2 and 3, respectively (additional data is shown 
in Supplementary Table 1 and 2, respectively). The 
upregulated expression of these genes in breast cancer was 
confirmed using data contained at Oncomine (Figure 1B).
Combined analyses of GTSE1, CDCA3, 
FAM83D and SMC4 predicts poor RFS and OS 
in Luminal A tumors
When combined, the expression of GTSE1, CDCA3, 
FAM83D and SMC4 was significantly associated with 
worse RFS (HR 2.14, CI: 1.64-2.8; log rank p=1.2e-08) 
(Figure 4). Additionally, the combination of CDCA3 and 
FAM83D showed the highest effect on RFS (HR 2.34, 
CI: 1.78-3.08; log rank p=3.60e-10) (Table 1A). No 
association between these genes and RFS was observed for 
luminal B tumors (Supplementary Table 1). Similarly, a 
detrimental effect was observed for OS with the combined 
analyses of the four genes (HR 2.3; CI: 1.27-4.18; log 
rank p=0.0049) (Figure 5), but GTSE1 alone predicted the 
greatest magnitude of effect (HR 3.23; CI: 2.11-4.94; log 
rank p=1.2e-08) (Figure 3, and Supplementary Table 2). 
Of note, neither combination among genes was better than 
FAM83D and CDCA3 for RFS, and GTSE1 for OS (Table 
1A and 1B, and Supplementary Table 2, respectively).
Association with outcome by nodal status and 
treatment with chemotherapy
Next we evaluated the association of these genes 
alone or in combination with outcome by nodal status and 
chemotherapy treatment. GTSE1 and the combination 
Figure 2: Association of GTSE, CDCA3, FAM83D and SMC4 individually with relapse free survival in Luminal A 
tumors using KM Plotter online tool, as described in material and methods.
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Figure 3: Association of GTSE, CDCA3, FAM83D and SMC4 individually with overall survival in Luminal A tumors, 
using KM Plotter online tool, as described in material and methods.
Figure 4: Association of the combined analyses of GTSE, CDCA3, FAM83D and SMC4 with relapse free survival in 
Luminal A. and B. tumors using KM Plotter online tool, as described in material and methods.
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of GTSE1, SMC4, FAM83D and CDCA3 predicted 
detrimental outcome for RFS in patients with both axillary 
positive and negative lymph nodes (Supplementary 
Table 3). Expression of GTSE1 was associated with poor 
OS in both subgroups. Similarly, GTSE1 predicted for 
detrimental RFS and OS in patients treated with or without 
chemotherapy, and the combination of the four genes 
predicted for RFS (Supplementary Table 3).
Molecular alterations or copy number gains in 
the evaluated genes and potential druggable 
targets
Supplementary Table 4 describes the function 
of these genes. Finally, we evaluated if the association 
of these genes with outcome could be related to 
molecular alterations such as mutations or copy number 
modifications. CDCA3 was amplified in 3.4% of the 
tumors, and FAM83D and SMC4 in 2.3% and 2.2%, 
respectively (Supplementary Table 5). Finally using the 
Drug Gene Interaction Database (DGIdb) (http://dgidb.
genome.wustl.edu/) we explored compounds that could 
potentially interact with the identified genes. Only the 
compound hydrochlorothiazide showed potential for 
interaction with CDCA3. No compound was found for 
potential interaction with GTSE1, FAM83D or SMC4.
DISCUSSION
We have discovered a set of genes that identify 
luminal A patients with worse outcome. It is known that 
most patients that harbor luminal A tumors are treated 
with endocrine therapy. However, a subset of these tumors 
does not respond adequately to this treatment and have 
Table 1: A. Association with Relapse Free Survival of gene combinations in Luminal A tumors. B. Association with 
Overall Survival of gene combinations in Luminal A tumors 
A
Relapse Free Survival. Luminal A
Gene Symbols Hazard Ratio P-value
GTSE1 + CDCA3 1.82 7.40E-06
GTSE1 + FAM83D 2.09 3.80E-08
GTSE1 + SMC4 1.41 1.40E-04
CDCA3 + FAM83D 2.34 3.60E-10
CDCA3 + SMC4 1.7 6.20E-05
FAM83D + SMC4 1.85 3.40E-06
CDCA3 + FAM83D + GTSE1 2.03 1.40E-07
CDCA3 + FAM83D + SMC4 1.97 3.60E-07
FAM83D + GTSE1 + SMC4 1.91 9.90E-07
B
Overall Survival. Luminal A
Gene Symbols Hazard Ratio P-value
GTSE1 + CDCA3 2.02 0.017
GTSE1 + FAM83D 2.48 2.40E-03
GTSE1 + SMC4 2.13 1.30E-04
CDCA3 + FAM83D 2.22 7.20E-03
CDCA3 + SMC4 1.99 0.019
FAM83D + SMC4 2.17 9.10E-03
CDCA3 + FAM83D + GTSE1 2.57 1.60E-03
CDCA3 + FAM83D + SMC4 2.26 6.00E-03
FAM83D + GTSE1 + SMC4 2.52 2.00E-03
KM Plotter online tool was used as described in material and methods
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poor prognosis. In this context, the identification of a 
subgroup of patients within the luminal A subtype with a 
poor prognosis could help to stratify patients and consider 
alternative therapeutic strategies for them.
In our study by using transcriptomic analyses we 
identified genes that are overexpressed in breast cancer 
and linked with cell division. Among the genes commonly 
shared in the analyses, only four were associated with poor 
RFS and OS in luminal A tumors. Of note, the analyses 
of GTSE1 for OS and FAM83D and CDCA3 for RFS 
showed the worse outcome, an observation seen only in 
luminal A tumors.
CDCA3, FAM83D and SMC4 genes were found 
to be amplified in a very small percentage of tumors. 
The reduced presence of molecular alterations or copy 
modifications at a genomic level, lead us to consider 
these markers as an indirect measure of tumors with high 
proliferation capacity. It can be considered that these genes 
are not oncogenic drivers but may be indirect indicators 
of tumors that are more dependent of cell division and 
mitosis. In this context, tumors with these markers could 
be more sensitive to agents that target cell cycle or even 
cytotoxic chemotherapy. Therefore, these genes may have 
utility in identifying patients for such treatments.
CDCA3 has been associated with both cancer risk 
[7] and poor prognosis in certain tumors [8]. High levels 
of FAM83D have been associated with poor outcome in 
several tumors and an increase in proliferation in vitro 
models [9, 10]. SMC4 belongs to a family of genes linked 
with poor outcome in prostate cancer [11], and finally, 
GTSE1 was described as associated with worse prognosis 
in uterine leimyosarcoma [12].
It should be mentioned that one of the identified 
genes that was differentially expressed was MKi67, the 
gene that encodes for Ki67. As this gene is currently used 
to select between luminal A and B tumors, therefore it was 
not included in our evaluation. However, the magnitude 
of association between the expression of MKi67 and poor 
outcome was lower than the selected genes.
In addition it should be noted that the genes 
identified are not druggable targets as can be seen from 
our analyses, with the exception of hydrochlorothiazide 
that could have a potential interaction with CDCA3.
A limitation of our study is a potential heterogeneity 
in the treatment the patients received. Although it can 
be expected that most estrogen-positive patients were 
treated with endocrine therapy, this cannot be confirmed. 
Also, the results are based on univariable analysis as 
there was insufficient information on patient and tumor 
characteristics to inform a multivariable model. This, in 
addition to survival data which were available for only a 
small number of patients, suggests that results should be 
considered hypotheses generating and should be validated 
in a large independent cohort. Our analysis focused on 
proliferation. It is known that other biological functions 
beyond mitosis can differentiate between luminal A and B 
tumors. Finally, it should be mentioned that information 
contained at Oncomine does not distinguish among breast 
cancer subtypes.
In conclusion, we describe a set of genes that 
are overexpressed in luminal A tumors that predict for 
detrimental outcome. These biomarkers could help to 
stratify therapies including treatment with antimitotic 
agents or cytotoxic chemotherapy.
Figure 5: Association of the combined analyses of GTSE, CDCA3, FAM83D and SMC4 with overall survival in 
Luminal A. and B. tumors using KM Plotter online tool, as described in material and methods.
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MATERIALS AND METHODS
Transcriptomic analysis and identification of 
upregulated genes
mRNA level data from normal breast tissue 
and basal-like and non-basal like breast tumors 
were extracted from a public dataset (GEO DataSet 
accession number: GDS2250)[13, 14]. Affymetrix CEL 
files were downloaded and analyzed with Affymetrix 
Transcriptome Analysis Console 3.0. Only genes with 
minimum 4-fold differential expression values between 
control and other groups were selected. The list of 
genes was analyzed using gene set enrichment analyses 
using DAVID Bioinformatics Resources 6.7 in order to 
identify functions of these genes (https://david.ncifcrf.
gov/). We used an adjusted p-value <0.05 to select the 
enriched gene-sets. The differentially expressed genes 
were independently confirmed using data contained at 
Oncomine (www.oncomine.org) (TCGA Breast). For 
this analysis, due to the absence of breast cancer subtypes 
in this dataset we compared normal breast with breast 
cancer.
Outcome analyses
The KM Plotter Online Tool (http://www.kmplot.
com)[6] was used to evaluate the relationship between the 
presence of different genes and patient clinical outcome in 
different breast cancer subtypes.
This publicly available database allows to 
investigate overall survival (OS) and relapse-free survival 
(RFS) in luminal A, luminal B and basal-like breast 
cancers.
Definitions of breast cancer subtypes
Breast cancer subtypes in the KM Plotter Online 
tool are defined as follow: Triple negative: ESR1-/HER2-
. Luminal A: ESR1+/HER2-/MKI67 low. Luminal B: 
ESR1+/HER2-/MKI67 high and ESR1+/HER2+ -.
Evaluation of molecular alterations
We used data contained at cBioportal (www.
cbioportal.org) (TCGA dataset) to explore the role of 
mutations, deletions or amplifications in the identified 
genes [15].
Evaluation of gene-drug interactions
For the evaluation of compounds that could 
potentially interact with the identified genes we used the 
Drug Gene Interaction Database (DGIdb) (http://dgidb.
genome.wustl.edu/).
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